mRNA technology

mRNA technology, which proved instrumental in the rapid development of COVID-19 vaccines, is now at the forefront of discussions for a new type of flu vaccine. The U.S. Food and Drug Administration (FDA) advisory committee is currently debating the approval of Moderna's mFlusiva, a first-of-its-kind flu shot utilizing this innovative platform. This potential new vaccine is being considered as an option for individuals aged 50 and older, with a decision anticipated before the upcoming winter flu season. The current deliberations highlight the expanding applications of mRNA technology beyond its initial success in combating the COVID-19 pandemic, signaling a significant advancement in vaccine development for other infectious diseases.